Stereotaxis, Inc. 10-Q Summary: Period Ended June 30, 2009
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Stereotaxis, Inc., a developer of magnetic navigation systems for interventional cardiology, for the period ended June 30, 2009. The company designs, manufactures, and markets the NIOBE system for image-guided catheter delivery and the ODYSSEY information management system. The financial statements are unaudited.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 |
|---|---|---|
| Total Revenue | $23,777,474 | $17,687,042 |
| Gross Margin | $15,650,909 (66%) | $11,078,343 (63%) |
| Operating Loss | $(13,781,788) | $(25,425,602) |
| Net Loss | $(14,969,864) | $(26,320,826) |
| Cash and Equivalents (End of Period) | $12,779,581 | $11,358,470 |
| Total Debt (Carrying Amount) | $28,397,978 | $29,173,038 |
| Working Capital | $(3,373,880) | $23,331,906 |
Debt Structure: Total debt includes $14.9 million in short-term obligations and $13.5 million in long-term debt. Significant portions relate to a revolving credit facility with Silicon Valley Bank and a royalty advance agreement with Biosense Webster.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 34% year-over-year (YoY) to $23.8 million, driven by a 22% increase in system sales and a 62% increase in disposables, service, and accessories revenue.
- Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) dropped 27% to $6.9 million, and General and Administrative (G&A) expenses fell 32% to $7.4 million, primarily due to reduced headcount and non-cash compensation.
- Liquidity Deterioration: The company moved from a positive working capital position of $23.3 million in December 2008 to a deficit of approximately $3.4 million in June 2009. This shift was caused by cash burn, the reclassification of $11 million of debt to short-term, and the reclassification of $4.8 million of warrants from equity to current liabilities due to the adoption of EITF 07-05.
- Net Loss Improvement: Net loss narrowed by 43% to $15.0 million, aided by revenue growth and cost-cutting measures.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects negative cash flow from operations throughout 2009. The company believes existing cash and borrowing facilities will fund operations for the next 12 months, assuming the renewal of credit facilities expiring March 31, 2010.
- Financing Needs: The company may require additional financing in the future. Failure to secure funding could force delays in R&D or commercialization.
- Key Risks:
- Debt Covenants: The company must maintain a minimum "tangible net worth" under its credit agreement.
- Foreign Exchange: Approximately 29% of revenue is denominated in foreign currencies; a 10% strengthening of the USD could reduce revenue by $0.7 million.
- Derivative Liability: Warrants issued in December 2008 are classified as liabilities and remeasured quarterly, impacting net income based on fair value changes.
- Management Commentary: The company is focusing on commercialization, with R&D and G&A expected to decrease while sales and marketing expenses are expected to increase.
Investor Verification Checklist
- Debt Maturity: Verify the status of the $25 million revolving credit facility and the $10 million affiliate commitment, both expiring March 31, 2010.
- Working Capital Deficit: Confirm the company's ability to service short-term debt of $14.9 million given the negative working capital position.
- Warrant Liability: Monitor the fair value adjustments of the $4.5 million warrant liability, which directly impacts reported net income.
- Biosense Webster Agreement: Review the terms of the $14.5 million royalty advance and the "Accelerating Recoupment Event" triggers that could accelerate repayment.
- Leadership Transition: Note the appointment of Daniel J. Johnston as CEO, effective November 15, 2009.